drugset
drugset / Trial / NCT00468169

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

NCT00468169 ↗

Phase 2 Completed 110 enrolled University of Chicago Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®) added to two concurrent chemoradiotherapy platforms of different intensity in locally advanced head and neck cancer.

Timeline

Start
2006-07
Primary completion
2012-08
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 —
Subject Cisplatin Other / unclassified 100 mg/m2 —
Subject Hydroxyurea Other / unclassified 500 mg Oral
Subject fluorouracil Small molecule 600 mg/m2 —

Indications

head and neck cancer